Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose calcineurin inhibitor plus sirolimus after kidney transplantation in recipients of kidneys from donors over 50 years old
ChiCTR2500103759Phase 4Completed
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sirolimus in end-stage kidney disease (ESKD) (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Glomerular filtration rate. Started Jun 2025; status: completed.
02
Drugs
sirolimus
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2500103759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103759.